TNON Share Price Performance
US$6.83
-45.32 (-86.90%)
93.5% undervalued intrinsic discount
US$105.00
Fair Value
Price US$6.83
AnalystHighTarget US$105.00
AnalystConsensusTarget US$2.88
AnalystLowTarget US$2.25
Fair ValueUS$105.00
Share Pricen/a
Tenon Medical, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
TNON Community Narratives
AN
Fair Value
·Fair Value US$105 93.5% undervalued intrinsic discount
Multiple Sacral Pelvic Approaches And Expanding Patent Estate Will Drive Long Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$2.88 137.6% overvalued intrinsic discount
SiVantage Acquisition And Diversified Platforms Will Expand Market Reach
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$2.25 203.6% overvalued intrinsic discount
Training Bottlenecks And Regulatory Risks Will Challenge Sacroiliac Fusion Momentum Yet Eventually Support Gains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Multiple Sacral Pelvic Approaches And Expanding Patent Estate Will Drive Long Term Upside
Tenon Medical aims to grow by giving spine surgeons more than one way to treat the same lower-back joint problem, which could make its devices easier to adopt in both first-time and repeat procedures. The catch is it’s still losing money, so the upside depends on training converting into regular use and new product rollouts staying on track.Read more
AN
US$105
93.5% undervalued intrinsic discount
Fair Value
Profit Margin
12.13%
Future PE
N/A
Price in 2029
US$0
Training Bottlenecks And Regulatory Risks Will Challenge Sacroiliac Fusion Momentum Yet Eventually Support Gains
Tenon Medical is trying to ride growing demand for a specific spine procedure, but its progress may hinge on how quickly doctors get trained and hospitals approve the tools. New device options and a stronger training push could help over time, yet delays, slower adoption, or ongoing cash needs could keep the story bumpy.Read more
AN
US$2.25
203.6% overvalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
14.46x
Price in 2029
US$1.72
SiVantage Acquisition And Diversified Platforms Will Expand Market Reach
Key Takeaways Acquisition and product launches boost market penetration, clinical adoption, and future revenue, while reducing dependence on a single product line. Strong cost control and a debt-free balance sheet enhance flexibility for innovation, supporting potential margin improvement and lowering financial risk.Read more
AN
US$2.88
137.6% overvalued intrinsic discount
Fair Value
Profit Margin
12.49%
Future PE
12.11x
Price in 2028
US$1.83
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
TNON: Nasdaq Listing Plan And Cash Runway Will Drive Repricing
Fair Value: US$105 93.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Training Bottlenecks And Regulatory Risks Will Challenge Sacroiliac Fusion Momentum Yet Eventually Support Gains
Fair Value: US$2.25 203.6% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SiVantage Acquisition And Diversified Platforms Will Expand Market Reach
Fair Value: US$2.88 137.6% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Tenon Medical, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -20.53
- 66.81%
- -257.85%
- -248.5%
About TNON
- Founded
- 2012
- Employees
- 26
- CEO
- WebsiteView website
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive inferior-posterior approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
